Cortechs.ai | Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai accelerates strategic expansion into European market

Cortechs.ai grows quantitative brain imaging operations in Europe

(San Diego, CA) May 26, 2016 – Cortechs.ai, the leading medical software innovator providing trusted solutions for quantitative brain analysis, is pleased to announce the acceleration of its international expansion to the European market to address the growing demand for quantitative imaging solutions and to support its existing customer base in Europe.

Cortechs.ai’ flagship solution, NeuroQuant®, received CE mark clearance in 2014, paving the way for many European customers to use Cortechs.ai’ fully automated quantitative brain imaging solutions in clinical practice. Cortechs.ai’ quantitative imaging solutions, NeuroQuant and PETQuant™ provide neurologists, radiologists, and clinical researchers with accurate and convenient tools to quantify the volumes of specific brain structures providing evidenced-based assessments of brain atrophy which could be caused by neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

In conjunction with the expansion into Europe, Cortechs.ai has hired Peter Segers, MSc, to head the European team. Mr. Segers joins the company with over 18 years of market and business development experience in medical devices, with senior roles at Lightpoint Medical, Nucletron and BMEYE, as well as, Philips Medical Systems. He brings a wealth of expertise in building global enterprise relationships and has an extensive knowledge of medical imaging market. Mr. Segers is based out of Amsterdam.

“Our international expansion is a critical step in providing continuing access and support of Cortechs.ai’ proven and reliable quantitative volumetric analysis solutions,” said Guri Stark, CEO of Cortechs.ai. “NeuroQuant has experienced impressive acceptance and success in prominent clinical institutions in the US and we are excited to see the demand and growth in Europe as we expand our solutions and launch our new Multiple Sclerosis products later this summer.”

For more information about Cortechs.ai brain imaging analysis solutions, please visit Stand D40 at the 2nd Congress of the European Academy of Neurology (EAN) taking place May 28-31 in Copenhagen.

PETQuant is available for research use only.

About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis solutions provide neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

 

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

Scroll to Top